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Estimating the mental health costs of racial
discrimination
Amanuel Elias* and Yin Paradies
Abstract
Background: Racial discrimination is a pervasive social problem in several advanced countries such as the U.S., U.K.,
and Australia. Public health research also indicates a range of associations between exposure to racial discrimination
and negative health, particularly, mental health including depression, anxiety, and post-traumatic stress disorder
(PTSD). However, the direct negative health impact of racial discrimination has not been costed so far although
economists have previously estimated indirect non-health related productivity costs. In this study, we estimate the
burden of disease due to exposure to racial discrimination and measure the cost of this exposure.
Methods: Using prevalence surveys and data on the association of racial discrimination with health outcomes
from a global meta-analysis, we apply a cost of illness method to measure the impact of racial discrimination.
This estimate indicates the direct health cost attributable to racial discrimination and we convert the estimates to
monetary values based on conventional parameters.
Results: Racial discrimination costs the Australian economy 235,452 in disability adjusted life years lost, equivalent
to $37.9 billion per annum, roughly 3.02% of annual gross domestic product (GDP) over 2001–11, indicating a
sizeable loss for the economy.
Conclusion: Substantial cost is incurred due to increased prevalence of racial discrimination as a result of its association
with negative health outcomes (e.g. depression, anxiety and PTSD). This implies that potentially significant cost savings
can be made through measures that target racial discrimination. Our research contributes to the debate on the social
impact of racial discrimination, with implications for policies and efforts addressing it.
Keywords: Burden of disease, DALY, Health cost, Racial discrimination, Australia
Background
Introduction
Existing scholarship acknowledges the cost of racial
discrimination and its disproportionate bearing on racial
minorities [1–3]. However, the economic consequences
experiences of racial discrimination (EOD) extend be-
yond the immediate targets to those witnessing discrim-
ination [4] and even to the perpetrators themselves
[5–7]. Flow on effects can occur for the targets’ immedi-
ate and/or extended families [8–10], communities, and
government institutions that are tasked with combating
discrimination. At an aggregate level, the country can
incur losses in terms of direct healthcare expenditures
arising from the health-related impact of racism and
indirectly in the form of forgone output related to em-
ployment discrimination.
The purpose of this study is to cost the negative men-
tal health outcomes associated with exposure to EOD.
We apply a step by step costing method to estimate the
health impact of EOD, focusing on four key health out-
comes including depression, anxiety, post-traumatic
stress disorder (PTSD) and psychological disorder.
In this and the next section, we discuss related litera-
ture and the methods involved including the data we
utilise in our analysis. Then, we present the results
reporting burden of disease estimates, DALYs and health
cost estimates. We also report a sensitivity analysis,
taking three scenarios, each assuming alternative param-
eters. We then discuss the findings, before presenting a
brief conclusion.* Correspondence: amanuel.h@deakin.edu.au
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Related research
Although there has been research on employment-related
costs of discrimination [11], intangible costs that manifest
in terms of pain and suffering arising from the physical
and psychological illnesses may also be considerable. A
wide body of evidence has documented the negative health
outcomes associated with experiences of racial discrimin-
ation (EOD) [12–16]. However, to our knowledge, no pre-
vious study has so far estimated these health-related costs
in monetary terms. In this study, we attempt to fill this gap
by estimating the dollar value of these intangible health re-
lated costs from a societal perspective, focusing, particu-
larly, on mental illnesses. Using Australian prevalence data
and association data from a recent meta-analysis [14], we
calculate burden of disease (BoD) estimates in terms of dis-
ability adjusted life years (DALYs) for outcomes with the
requisite data.
Previously, estimations of the economic cost of EOD
followed the neoclassical approach which generally focuses
on indirect costs related to productivity loss as a result of
discrimination premiums [17, 18]. In labour economics,
these costs are measured as differentials in wages, earnings,
employment, promotion and labour supply (see [19–21] for
reviews). Similarly, literature at the intersection of law and
economics has been limited to detecting evidence of racial
discrimination rather than estimating its human and social
impact. Another literature related to the housing market,
measures EOD-related costs to minority group customers
in terms of potential indirect costs, associated with higher
prices and limited services [22, 23].
So far, only a handful of studies have gone beyond a
focus on the indirect microeconomic impact in estimating
the cost of EOD. Although these studies are also based on
indirect productivity loss (i.e., opportunity costs to busi-
nesses), they have attempted to estimate the potential ag-
gregate effect of EOD in an economy [24–26]. The
estimations attribute the costs to foregone wages for mi-
norities, and indirectly measure losses in national output
from an industry perspective.
Health cost estimation
Depending on the prevalence of EOD and the degree of
association between EOD and health outcomes, EOD can
also be seen as a public health issue as it can affect the
overall wellbeing and quality of life of a society. This as-
pect of the cost of EOD can be assessed using cost of ill-
ness methods which are widely utilised in health
economics. Using this approach, the cost of EOD can be
conceptualised in terms of health outcomes from an indi-
vidual/societal perspective where the health burden is
largely borne by individuals, and cumulatively by a society,
in the form of physical and mental illnesses.
Following the cost of illness literature [27–29], the
cost of EOD can either be determined by identifying the
cost components from different perspectives (industry/
business, government, or society) or classified into three
distinct components: direct costs, indirect costs and in-
tangible costs. Taking the latter classification, the direct
cost component of EOD would include all the health re-
lated costs that are immediate consequences of discrim-
ination. These costs include health sector costs such as
outpatient costs, prescription drug purchases, medical
fees etc. Other direct cost components include those
borne by different sectors of an economy including pro-
duction and consumption related costs, administrative,
welfare/transfer and other costs.
Indirect costs involve productivity loss and other em-
ployment related costs associated with EOD. The loss in
productivity includes, for instance, the costs incurred by
employers due to absenteeism, resulting from the target
having to cope with depression, physical illness, hospital
visits etc. In addition, costs due to lower performance at
work by employees exposed to discrimination are in-
cluded. Potentially, however, the largest amount of ill-
ness cost due to EOD would come from the intangible
cost component. In this paper, we estimate this aspect of
the health cost of EOD. Intangible costs involve the pain,
suffering and premature death associated with a risk fac-
tor/health outcome. For example, depression and related
symptoms associated with EOD affect the wellbeing of
targets. This and other associated illnesses can be in-
cluded in the estimation of loss in wellbeing in terms of
disability adjusted life years (DALYs), the tool widely
used in costing a range of epidemiological conditions
[27, 30]. This tool allows us to determine the burden of
disease (BoD) fractions of illnesses arising from the tar-
gets’ exposures to discriminatory episodes.
Methods
Data
In this study, the individual target is the unit of reference.
We use Australian self-report data from three nationally
representative surveys (the Scanlon Foundation’s Mapping
Social Cohesion (MSC) survey, the Challenging Racism
Project (CRP) and the 2012 National Dual-frame Omni-
bus Survey (DFO)) to estimate the prevalence of EOD.
We utilise these prevalence data along with the magnitude
of association between racism and four key health out-
comes from a recent comprehensive meta-analysis [14] to
calculate BoD estimates ascribed to EOD through loss of
DALYs. We then use the results to compare the current
health status with a counterfactual of no lifetime discrim-
ination. Finally, we convert these estimates into monetary
estimates using standard parameters. We then conduct
sensitivity analysis for the robustness of the cost estima-
tions, using three scenarios of the valuation of life (low,
medium and high value of statistical life - VSL) and a
range of discount rates.
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Prevalence of EOD and its association with health
Racial discrimination is usually measured either based on
self-report or observational data [31]. One advantage of
self-report data in discrimination research is that it enables
researchers to directly measure the experiences of the tar-
gets [32–34]. Unlike observational data, it does not rely on
observed differentials in the outcomes (e.g. wages and salar-
ies, years of schooling etc.) of different racial groups per se
to determine the prevalence of EOD. Self-report data can
extract more complete data on EOD as perceived by targets
themselves. However, self-report data can be susceptible to
reporting bias [35]. Respondents may not correctly under-
stand the question; they may over report their experiences
(vigilance bias); or they may underreport them (minimisa-
tion bias). Yet, research to-date indicates that under- rather
than over-reporting is more prevalent, in relation to racial
discriminaton [36, 37]. Noting the strengths and drawbacks
of self-report data, we utilise the three national surveys
mentioned above to estimate EOD among Australian
respondents.
Measures
Prevalence of EOD in Australia
Our first EOD measure is from the CRP survey (n = 12,512)
which consists a series of surveys conducted between 2001
and 2008 in different states in Australia [38]. The EOD
measure from this study has six items with 5-point Likert
type responses where 22.3% of the respondents reported ex-
periencing racial discrimination. The second dataset, the
MSC survey (n = 2000 in each wave), was conducted be-
tween 2007 and 2013 [39]. A dichotomous EOD measure
in this survey indicates that 9–19% of respondents re-
ported EOD over the period 2007–13. The DFO survey
(2012, n = 2000), another Australian dataset conducted by
the Social Research Centre, contains three items on ra-
cism as well as general health, physical activity, smoking,
and substance use. Responses were coded 1 = yes and 2 =
no, and almost 20% of the respondents indicated experi-
encing racial discrimination.
The prevalence data we utilise in this study classifies
respondents first by gender, then by age into seven age cat-
egories, ranging 18–100 years. Table 1 below summarises
the distribution of EOD in the three datasets based on age
and gender. To generate a weighted average EOD data
from the three national surveys, we first dichotomised the
5-point CRP EOD data, before decomposing the result by
age and gender. EOD responses including “sometimes” and
over were recoded as “1” while the rest were recoded as “0”.
The last two columns of Table 1 indicate that the average
prevalence of EOD among those aged 64 years and below
ranged 13.4 to 20.1%.
Association between EOD and health outcomes
A comprehensive assessment of the overall cost of EOD
requires estimates of the health impact of exposure to
EOD. As part of a recent meta-analysis, we investigated
293 studies, and found significant unadjusted associations
between EOD and some key health outcomes, ranging
from depression to hypertension, based on studies pub-
lished until October 2013 [14]. Subject to our inclusion
and exclusion criteria, we identified more than 21 associa-
tions of EOD and major health outcomes.1 However, in
this study, we focus on only four illnesses across 102 stud-
ies, because the rest are either co-morbid with illnesses
such as depression, or they are not available in the Global
Burden of Disease which is the basis of our analysis. For
example, chronic stress is associated with depression, and
depression in turn is associated with obesity [40, 41].
In most cases, the studies we included utilise standard
measures. For example, the instruments used in depres-
sion studies include the Centre for Epidemiological
Studies Depression scale, the Major Depression Epi-
sodes, and the Beck Depression Inventory. For anxiety,
studies utilised instruments such as the State Trait
Table 1 Prevalence of racial discrimination in Australia by age and gender
Age group Gender
CRP MSC DFO Weighted average
Males Females Males Females Males Females Males Females
17–24 32.7 24.8 20.0 14.6 18.8 23.5 23.8 20.1
25–34 33.6 21.8 16.5 13.4 25.7 32.5 22.3 19.0
35–44 28.5 21.8 13.2 12.9 22.7 23.7 18.5 18.0
45–54 26.6 19.9 12.7 11.6 13.8 23.4 17.0 16.5
55–64 24.8 15.6 7.9 9.7 17.4 20.1 13.7 13.4
65–74 14.8 10.7 5.2 5.7 10.0 16.8 8.4 9.0
75–100 9.7 7.2 5.1 0.6 4.7 13.3 6.4 4.8
Note: Values are percentages of those who indicated they experienced racial discrimination in their lifetime. The last two columns are estimated based on the
weighted average from CRP, MSC & DFO data
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Anxiety Index, the Beck Anxiety Inventory and the Gen-
eral Health Questionnaire.
To allow an unbiased estimation of BoD attributable to
EOD, the ideal effect size would be risk ratio (RR), indicat-
ing the prevalence rate of the health outcome among the
exposed group relative to the unexposed group. However,
almost all of the included studies (94.1%) had insufficient
data for the calculation of RR. Given sufficient data, it is
possible to convert odds ratios (OR) to RR using the for-
mula proposed by Zhang & Yu [42]. However, the preva-
lence of the outcome on the control (unexposed) group
was not reported for most of the studies reporting OR
(and other OR convertible estimate). Therefore, only asso-
ciations based on ORs (n = 197) were utilised in this paper,
resulting in a focus on 101 studies (reported in 128 arti-
cles) involving 83,057 participants in total. There is a limi-
tation in using OR in BoD analysis in that it exaggerates
the risk of the outcome if the outcome of interest is com-
mon [43, 44]. However, Davies et al. [43] indicate that the
size of the exaggeration depends on the size of the OR.
Smaller OR would have minor exaggeration effect com-
pared to large OR, therefore, using OR as alternative for
RR would introduce minor exaggeration for OR < 3.0. In
this study, the OR for all the illnesses except PTSD is less
than three. Although we expect the OR for PTSD to have
some exaggeration effect, the impact on the overall study
findings is negligible given the small prevalence rate of
PTSD considered here along with the small disability
weight assigned to it in the GBD.
Within this association data, one issue that remained is
the heterogeneity in the measures where the outcome
scales varied from dichotomous (yes/no) categories to a
range of categories including 3 to 9-point Likert type
scales, and in some cases continuous measures. To
account for this heterogeneity, we report two types of
response categories. First, we report health outcomes for
dichotomous response measure as one group with associ-
ations comparing the EOD-exposed and unexposed re-
spondents. Second, we weight average the rest of the
exposure measures and report them as one group com-
paring those who had low with those who had high level
of EOD exposure (see Table 2). The sample size reported
in Table 2 varies by the number of studies included, with
depression having the largest overall sample (n = 124,049)
and PTSD having the least overall sample (n = 2621). All
associations were statistically significant (highly so in most
cases) with odds ratios of two to three for all health out-
comes except for PTSD.
Statistical analysis
DALYs, PAF and health costs
BoD analyses of risk factors/health outcomes are fre-
quently used in measuring the health impact of a range of
exposures. The health impact of EOD can likewise be esti-
mated using this method. The World Health Organisation
(WHO) provides guideline for the calculation of BoD.
Following this guideline, BoD can be defined as a measure
quantifying ‘the gap between a population’s current health
and an ideal situation where everyone lives to old age in
full health’ [29, p. 4]. It is numerically estimated in terms
of DALYs where a loss of one DALY is equivalent to a loss
of one healthy year of life [45]. Mathers et al. [46, p. 3] de-
scribe DALY as ‘a summary measure of population health
that combines in a single indicator, years of life lost from
premature death and years of life lived with disabilities.’
Several international studies have used BoD based on
DALY in cost estimations for a range of illnesses [47–49].
Although BoD represents direct health impact resulting
from the exposure, it is not a measure of immediate ex-
penditures. It exists as an opportunity cost that was lost or
a cost that can be averted. In different cost of illness stud-
ies, DALYs express the ‘pain, suffering and premature
Table 2 List of association between EOD and health outcomes categorised by major illnesses
Illness/Health outcome Statistical outcome
Odds ratio Lower limit (95% CI) Upper limit (95% CI) Z-value P-value Total sample size Number of associations
A. Exposure response: yes/no
Anxiety 2.050 1.758 2.391 9.140 0.000 13,216 13
Depression 2.051 1.811 2.323 11.319 0.000 70,115 32
PTSD 4.560 2.656 7.829 5.501 0.000 212 2
Psychological disorders 2.584 2.068 3.137 9.318 0.000 13,705 3
B. Exposure response: 3-point and over
Anxiety 2.275 1.619 3.279 4.922 0.019 11,228 37
Depression 2.386 1.987 2.870 9.499 0.005 53,115 90
PTSD 3.756 2.225 6.637 5.248 0.040 2021 9
Psychological disorders 2.018 1.445 2.944 4.793 0.030 3946 11
Note: This table reports the effect size of the association between EOD and health outcomes categorised by response types from a meta-analysis [14]. Panel A is
based on a dichotomous measure of EOD while panel B is based on EOD measured as a categorical variable with 3-point and over response options
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mortality’ component of the health costs. In this paper,
prevalence data is used to estimate these costs attributable
to racial discrimination. Either prevalence or incidence
measures are used in the literature in the calculation of
the BoD [45, 47]. Formally, DALY is calculated as:
DALY ¼ Years of Life Lost
þ Years Lived with Disability ð1Þ
where years of life lost is premature mortality due to expos-
ure to the risk factor/illness and years lived with disability is
the number of years of less than functional life attributable
to the risk factor/illness. In theory, exposure to EOD is
causally associated with some illnesses which are in turn
causes of mortality (e.g., anxiety and depression, see: [47]).
Due to the timing issue regarding the exposure to EOD
and the incidence/prevalence of death, the causal relation-
ship is likely to be confounded. In addition, mortality is
already excluded from the meta-analysis which is the basis
of our analysis, as racial discrimination per se appears to
have no immediate association with mortality [50]. There-
fore, assuming years of life lost = 0 in this analysis, the
measure to be estimated becomes:
DALY ¼ Years Lived with Disability ð2Þ
where:
YLD ¼ Prevalence  Duration  Weight ð3Þ
where ‘prevalence’ is the prevalence of the illness, ‘dur-
ation’ refers to the duration of the illness since its onset,
and ‘weight’ is the disability weight. To exploit the popula-
tion attributable fraction (PAF), data already estimated in
this paper, an alternative specification is used to estimate
the DALYs [51]. The duration of illness is replaced by the
PAF whereby the value will be interpreted as DALYs at-
tributable to the EOD as a risk factor. This is specified by:
DALY ¼ Prevalence  Weight  PAF ð4Þ
where PAF indicates the fraction measuring the degree
of causal relationship between EOD and the illness. The
PAF or BoD attributable to a risk factor (e.g., EOD) is
estimated using the standard formula:
PAF ¼
Xk
i¼0
pi RRi−1ð Þ
" #

Xk
i¼0
pi RRi−1ð Þ þ 1
" #
ð5Þ
where i stands for the exposure category and i ¼ 0
represents the baseline category (no exposure); pi is the
prevalence of the exposure (risk factor) for the ith cat-
egory; RRi is the relative risk for the group with i level of
exposure and is compared with no exposure. After some
algebraic manipulation and assuming the relative risk for
the unexposed group to be 1, this formula can be re-
written as:
PAF ¼
X
c
pcRRc−1
" #

X
c
pcRRc
" #
ð6Þ
where c stands for the category of interest. Since most
studies included for association estimation have no suffi-
cient data to calculate relative risk (RR) ratio for an out-
come, the formula we actually utilise in calculating the
PAF is:
PAF ¼
X
c
pcORc−1
" #

X
c
pcORc
" #
ð7Þ
Once we estimated the DALYs attributable to the preva-
lence of EOD, the next step is to convert them to monetary
value which we do so using the value of statistical life (VSL)
approach. A range of values have been suggested in the lit-
erature as conversion parameters [52–55]. These studies
suggest a VSL value ranging between 0.6 million and $19.1
million. A recent study by Andersson and Treich [56] re-
ports a wider range of a VSL of $261 thousand to $36 mil-
lion. The corresponding cost per DALY falls in the range of
$70,000-$175,000. Drawing from the literature, Access
Economics [57] uses a VSL of $3.7–9.6 million in measur-
ing the cost of domestic violence in Australia. This corre-
sponds to a conversion rate of $162,561 per DALY. In this
analysis, we use a rate close to this ($166,250) as it draws
from available evidence and best practice in an Australian
context. The conversion involved key parameters including
a VSL of $6.65 million, a 3.3% discount rate, and a time-
frame of 40 years. Our conversion rate is estimated using
the discounting formula:
VSL ¼
XValue of Life Years
1þ rð Þt ð8Þ
where r is the discount rate. Value of life years is multi-
plied by DALY for each health outcome to convert the
latter to a monetary value that represents the health cost
attributable to the risk factor, an estimation we report in
the next section.
Results
Population attributable fractions
The third stage of our analysis combines the prevalence
measure of EOD and the corresponding association effect
sizes we use to estimate population attributable fractions
(PAFs). Tables 3 and 4 report the EOD related PAFs for
males and females, for each of the illnesses which have
statistically significant association with EOD. These tables
report the proportion of the prevalence of the designated
illness attributable to the prevalence of EOD. Table 3,
which was calculated assuming no exposure to EOD, indi-
cates that reducing EOD to zero can result in a 20% re-
duction in the prevalence of depression among men aged
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Table 3 Population attributable fractions: the prevalence of illness attributable to EOD (dichotomous) by age and gender
Age group Illness/Health outcome
Depression Anxiety PTSD Psychological disorders
PAF (%) 95% CI PAF (%) 95% CI PAF (%) 95% CI PAF (%) 95% CI
Males
17–24 20 (16.2–23.9) 20 (15.3–24.9) 45.9 (28.3–61.9) 27.4 (20.3–33.7)
25–34 19 (15.3–22.8) 19 (14.4–23.7) 44.2 (26.9–60.3) 26.1 (19.2–32.2)
35–44 16.2 (13.0–19.6) 16.2 (12.3–20.4) 39.6 (23.4–55.8) 22.6 (16.5–28.3)
45–54 15.2 (12.1–18.4) 15.1 (11.4–19.1) 37.7 (22.0–53.7) 21.2 (15.4–26.6)
55–64 12.6 (10.0–15.3) 12.6 (9.4–16.0) 32.7 (18.5–48.3) 17.8 (12.7–22.6)
65–74 8.1 (6.4–10.0) 8.1 (6.0–10.5) 23 (12.2–36.5) 11.8 (8.2–15.2)
75–100 6.3 (5.0–7.9) 6.3 (4.7–8.2) 18.7 (9.6–30.6) 9.3 (6.4–12.1)
Females
17–24 17.4 (14.0–21.0) 17.4 (13.2–21.8) 41.7 (25.0–57.8) 24.1 (17.7–30.0)
25–34 16.6 (13.3–20.1) 16.6 (12.6–20.9) 40.3 (23.9–56.4) 23.1 (16.8–28.8)
35–44 15.9 (12.7–19.2) 15.9 (12.0–20.0) 39 (22.9–55.1) 22.2 (16.1–27.7)
45–54 14.8 (11.8–17.9) 14.8 (11.1–18.6) 37 (21.4–53.0) 20.7 (15.0–26.0)
55–64 12.3 (9.8–15) 12.3 (9.2–15.7) 32.3 (18.1–47.7) 17.5 (12.5–22.2)
65–74 8.7 (6.8–10.7) 8.6 (6.4–11.1) 24.3 (13.0–38.1) 12.5 (8.8–16.1)
75–100 4.8 (3.7–5.9) 4.8 (3.5–6.2) 14.5 (7.3–24.6) 7 (4.9–9.3)
Note: All PAF values are percentages indicating the proportion of each illness attributable to exposure to racial discrimination and were calculated based on the
prevalence data discussed in the text. Values in parenthesis are confidence intervals
Table 4 Population attributable fractions: the prevalence of illness attributable to EOD (non-dichotomous) by age and gender
Age group Illness/Health outcome
Depression Anxiety PTSD Psychological disorders
PAF (%) 95% CI PAF (%) 95% CI PAF (%) 95% CI PAF (%) 95% CI
Males
17–24 27.8 (15.4–40.7) 24.8 (19.0–30.8) 29.5 (20.2–39.3) 23.4 (13.2–36.4)
25–34 26.5 (14.6–39.2) 23.6 (18.0–29.4) 28.1 (19.2–37.7) 22.3 (12.5–34.9)
35–44 23 (12.4–34.8) 20.4 (15.4–25.7) 24.5 (16.5–33.4) 19.2 (10.6–30.7)
45–54 21.5 (11.5–32.9) 19.1 (14.4–24.1) 23 (15.4–31.6) 17.9 (9.8–29.0)
55–64 18.1 (9.5–28.3) 15.9 (11.9–20.4) 19.4 (12.7–27.1) 15 (8.1–24.7)
65–74 12 (6.1–19.6) 10.4 (7.7–13.6) 12.9 (8.2–18.6) 9.8 (5.1–16.8)
75–100 9.4 (4.7–15.7) 8.2 (6.0–10.8) 10.2 (6.4–14.9) 7.7 (4.0–13.4)
Females
17–24 24.5 (13.4–36.7) 21.8 (16.6–27.3) 26.1 (17.7–35.4) 20.5 (11.4–32.6)
25–34 23.5 (12.7–35.4) 20.8 (15.8–26.2) 25 (16.8–34.0) 19.6 (10.8–31.3)
35–44 22.5 (12.1–34.2) 19.9 (15.1–25.1) 24 (16.1–32.8) 18.8 (10.3–30.2)
45–54 21 (11.2–32.3) 18.6 (14.0–23.6) 22.4 (15.0–31.0) 17.5 (9.6–28.4)
55–64 17.8 (9.3–27.9) 15.6 (11.7–20.0) 19 (12.5–26.7) 14.7 (7.9–24.3)
65–74 12.7 (6.5–20.7) 11.1 (8.2–14.4) 13.7 (8.8–19.7) 10.4 (5.5–17.8)
75–100 7.2 (3.5–12.1) 6.2 (4.5–8.2) 7.7 (4.9–11.5) 5.8 (3.0–10.3)
Note: All PAF values are percentages indicating the proportion of each illness attributable to exposure to racial discrimination and were calculated based on the
prevalence data discussed in the text. Values in parenthesis are confidence intervals
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17–24. A similar reduction of EOD can result in an 18.7%
reduction in the prevalence of stress among women aged
35–44. The rest of the values can be interpreted likewise.
Tables 4 is the non-dichotomous (3-point and above)
exposure measure version of Tables 3, reporting the pro-
portion of the prevalence of the designated illness attribut-
able to the prevalence of EOD among men and women
respectively. The values are calculated assuming EOD can
be reduced from high to the lowest theoretical minimum.
For example, reducing EOD to the lowest possible level
can result in a 23.6% reduction in the prevalence of anxiety
among men aged 25–34. A similar reduction of EOD can
result in a 22.4% reduction in the prevalence of PTSD
among women aged 45–54. Likewise, a reduction of EOD
to its theoretical minimum, would reduce the prevalence
of depression among men aged 25–34 years by 26.5%. This
would mean a 26.5% saving in the treatment cost of
depression in this age group. The rest of the values can be
interpreted similarly.
Disability Adjusted Life Years (DALYs)
Table 5 reports the final results of our BoD analysis. A total
of 235,452 DALYs per year is lost in Australia which can be
attributed to the prevalence of EOD. The number of DALYs
lost is relatively higher among women (DALY= 140,073)
compared to men (DALY= 95,397). Depression for women
(32.0%) and psychological disorders for men (33.8%) are the
leading causes. For men, depression accounts for 30.3% of
lost DALYs attributable to EOD. Overall, the loss in DALYs
caused by EOD is estimated to be 8.9% of DALYs from all
causes in Australia. This would place EOD above tobacco
as a major risk factor since tobacco was estimated to ac-
count for 204,788 in lost DALYs (according to the 2003
BoD in Australia, see [47]). A detailed version of this table
which disaggregates the findings by age groups is reported
in Tables 8 and 9 in Appendix.
The health costs of racial discrimination
The monetary estimate of the total DALYs attributable to
EOD allows for comparison with aggregate economic mea-
sures. Table 6 reports the health cost of EOD in Australia,
calculated using the value of statistical life (VSL) approach.
According to this estimation, EOD accounts for a total of
$37.9 billion in health cost to the Australian economy. This
is roughly 3.02% of the annual average GDP for the period
2001–11 (for GDP figures see [58]). The largest cost of
EOD, $11.9 billion, comes through its effect on depression.
This result is comparable with previous studies which used
a human capital approach to estimate the cost of EOD. Par-
ticularly, the Joint Economic Committee has reported that
EOD costed the U.S. economy 4% of GDP while Brimmer
[24] estimated the EOD cost to be $241 billion (3.8% GDP).
Sensitivity analysis
To check the robustness of the costs reported in Table 6,
we have conducted a sensitivity analysis. We look at three
scenarios where we use three VSL values: $3.7 million,
$6.65 million and $9.6 million. For each of these VSL
values, we varied the underlying discount rates in the 0–
10% range. The result, reported in Table 7, indicates a range
of health costs due to EOD. At the lower VSL scenario
(Panel A) the overall cost of EOD ranges between 1.6 and
1.7% of the average GDP for Australia for the 2001–11 pe-
riods. Using the highest discount rate of 10% yields an EOD
cost of $19.8 billion while a 0% discount rate results in
$21.8 billion. At a 3.3% discount rate the estimated cost is
$21.1 billion or 1.7% of GDP.
At the medium VSL value of $6.65 million (Panel B), the
health cost of EOD ranges between 2.9 and 3.1% of average
annual GDP (2001–11) [59]. This is $33 billion at a dis-
count rate of 10% and $39.1 billion at 0% discount rate, for
the discount rate of 3.3% the cost is $37.9 billion or 3% of
GDP. Similarly, at a high VSL of $9.6 billion (Panel C), the
cost is 4.1–4.5% of GDP or $51.4 billion for 10% discount
rate and $56.5 billion for 0% discount rate. At a 3.3%Table 5 EOD attributable burden of disease (DALYs) by gender
and causes in Australia
Cause/Illness Male (%) Female (%) Total
Anxiety 15,890 (16.7) 24,908 (17.8) 40,797
Depression 28,888 (30.3) 44,786 (32.0) 73,673
PTSD 18,366 (19.3) 32,776 (23.4) 51,142
Psychological disorders 32,235 (33.8) 37,604 (26.8) 69,840
Total of illnesses attributable
to EOD
95,379 (100) 140,073 (100) 235,452
DALYs from all causes in
Australiaa
1,364,614 1,268,156 2,632,770
Percentage of all DALYs
attributable to EOD
7.0% 11.0% 8.9%
Note: The values are DALYs attributable to the prevalence of EOD in a year.
The percentages in parentheses indicate DALYs caused by EOD as a
proportion of the total
aThis data was taken from The burden of disease and injury in Australia
2003 [49]
Table 6 Health cost of racial discrimination in Australia ($ millions)
Cause/Illness Men Women Total cost
Anxiety 2557 4009 6566
Depression 4649 7208 11,857
PTSD 2956 5275 8231
Psychological disordersa 5188 6052 11,240
Total of illnesses attributable
to EOD
15,350 22,543 37,893
Australian average annual
GDP (2001–2011)
1,256,769
Health cost of EOD as a percentage
of GDP
3.02%
Source (for GDP data): World Bank national accounts data, and OECD National
Accounts data files. GDP is in constant local currency unit (LCU)
aExcluding anxiety, depression and PTSD
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Table 7 Sensitivity analysis: health cost of racial discrimination in Australia ($ millions)
Cause of Illness DALYs Discount rate
0% 1% 2% 3% 3.3% 4% 5% 6% 7% 8% 9% 10%
Scenario A: VSL = $3.7 million
Anxiety 40,797 3774 3736 3700 3664 3653 3629 3594 3560 3527 3494 3462 3431
Depression 73,673 6815 6747 6681 6616 6597 6553 6490 6429 6369 6310 6252 6195
PTSD 51,142 4731 4684 4638 4593 4579 4549 4505 4463 4421 4380 4340 4301
Psychological disordersa 69,840 6460 6396 6333 6272 6254 6212 6153 6094 6038 5982 5927 5873
Total of illnesses attributable to EOD 235,452 21,779 21,564 21,352 21,145 21,084 20,942 20,742 20,547 20,354 20,166 19,981 19,799
Australian average annual GDP (2005–2012) 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769
Health cost of EOD as a percentage of GDP 1.7% 1.7% 1.7% 1.7% 1.7% 1.7% 1.7% 1.6% 1.6% 1.6% 1.6% 1.6%
Scenario B: VSL = $6.65 million
Anxiety 40,797 6783 6715 6650 6585 6566 6522 6460 6399 6339 6280 6222 6166
Depression 73,673 12,248 12,127 12,008 11,891 11,857 11,777 11,665 11,555 11,447 11,341 11,237 11,135
PTSD 51,142 8502 8418 8336 8255 8231 8175 8097 8021 7946 7873 7800 7729
Psychological disordersa 69,840 11,611 11,496 11,383 11,273 11,240 11,164 11,058 10,954 10,851 10,751 10,652 10,555
Total of illnesses attributable to EOD 235,452 39,144 38,756 38,376 38,004 37,893 37,638 37,280 36,928 36,583 36,244 35,912 32,960
Australian average annual GDP (2005–2012) 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769
Health cost of EOD as a percentage of GDP 3.1% 3.1% 3.1% 3.0% 3.0% 3.0% 3.0% 2.9% 2.9% 2.9% 2.9% 2.9%
Scenario B: VSL = $9.6 million
Anxiety 40,797 9791 9694 9599 9506 9479 9415 9325 9237 9151 9066 8983 8901
Depression 73,673 17,682 17,507 17,335 17,167 17,117 17,002 16,840 16,681 16,525 16,372 16,222 16,074
PTSD 51,142 12,274 12,152 12,033 11,917 11,882 11,802 11,690 11,579 11,471 11,365 11,261 11,158
Psychological disordersa 69,840 16,762 16,596 16,433 16,273 16,226 16,117 15,963 15,813 15,665 15,520 15,378 15,238
Total of illnesses attributable to EOD 235,452 56,508 55,949 55,400 54,863 54,703 54,335 53,818 53,310 52,812 52,323 51,843 51,371
Australian average annual GDP (2005–2012) 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769 1,256,769
Health cost of EOD as a percentage of GDP 4.5% 4.5% 4.4% 4.4% 4.4% 4.3% 4.3% 4.2% 4.2% 4.2% 4.1% 4.1%
Note: This table is a sensitivity analysis of the results reported in Table 6 at a range of discount rates for three scenarios: Panel A assuming a value of statistical life of $3.7 million, Panel B $6.65 million, and Panel C
$9.6 million. The benchmark discount rate and the associated values are indicated in bold numbers. Values reported in columns 1–11 are in millions of dollars unless indicated otherwise
aExcluding anxiety, depression and PTSD
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discount rate, EOD costs 4.4% of GDP, or $54.7 billion per
annum.
It can be concluded that the cost estimation varies de-
pending on the underlying parameters, discount rate
and VSL estimates. Using the same discount rate (3.3%),
the cost estimate variation across VSL estimates is in the
range of $21.1–$54.7 billion (1.7–4.4% of GDP).
Discussion
In this study, we estimated the economic value of reducing
EOD directly from an estimated BoD data. Using a cost of
illness method, we measured the PAFs for four key health
outcomes (depression, anxiety, PTSD and psychological
disorders). Our findings indicate substantial loss in DALYs
due to EOD. On the average, Australia loses up to 3.02% of
GDP per annum as a result of individuals being exposed to
some form of racial discrimination. Gender differences are
evident in the DALYs estimated due to the prevalence of
both racial discrimination and the illnesses. Empirical evi-
dence shows that the prevalence of psychological illnesses
tends to be higher among women than men [58, 60]. In
addition, the prevalence of EOD also tends to be higher
among women [59, 61, 62], as is evidenced in our data. This
corresponded with higher prevalence of mental illnesses,
leading to higher values of estimated DALYs.
The cost of illnesses estimates reported in this study re-
flect cost savings measured against their counterfactuals.
They can potentially be realised via measures that can re-
duce the prevalence of racial discrimination, as a risk factor,
to zero or the possible minimum. However, the findings we
report should be considered exploratory and indicative.
They do not necessarily represent immediately realisable
estimates. They are opportunity costs, costs that could be
saved by avoiding the need for treating the preventable dis-
ease [63]. A range of assumptions are involved in this esti-
mation, the causality of the relationship between EOD
exposure and health being the most important.
First, establishing causal relationship between EOD and
health outcomes from cross-sectional studies has limita-
tions as a target could be experiencing negative health out-
comes due to multiple factors. Reverse causation between
EOD and negative health outcomes cannot be ruled out al-
though there is considerable evidence suggesting that EOD
precedes ill-health [14, 64]. Obtaining association data in
terms of RR rather than OR should improve the accuracy
of the findings and solve the causality issue. Second, only
unadjusted associations between EOD and health are uti-
lised in this analysis. However, confounding due to multi-
variate effects in such associations cannot be ruled out. For
example, factors such as demographic and socio-economic
factors can also have a role in EOD and health outcomes. A
thorough investigation of longitudinal analysis and adjusted
associations should, therefore, give a better picture regard-
ing the BoD outcomes related to the EOD.
Our estimation of DALYs also has some limitations. First,
our study has estimated the cost of EOD for only four ill-
nesses although the literature indicates association with
physical illnesses such as hypertension, diabetes and hyper-
cholesterolemia [65]. This is likely to lead to the underesti-
mation of the health cost estimates reported. The main
reason for the exclusion of physical illnesses in this study is
insufficient data for the calculation of BoD estimates. Apart
from the four illnesses indicated in Table 5, we could not
use 21 associations we analysed in a meta-analysis for they
are not available in the Global Burden of Disease (GBD).
Either they are only risk factors which cannot be strictly
considered illnesses (e.g., overweight, obesity etc.) or they
are not defined in the GBD due to co-morbidity (e.g.,
stress, psychological distress, internalizing symptoms etc.).
For those which are not in the GBD categories no disability
weight data is available for the calculation of DALYs. For
mental/psychological disorder, a composite disability
weight index was used by averaging across all the mental
disorders weights available in the GBD, Vos & Mathers
[66] and Begg et al. [47].
Second, we could not find prevalence data for some ill-
nesses (e.g., stress, internalizing symptoms etc.). Therefore,
the requirement for the calculation of DALYs could be
completed for just four studies. The association data was
obtained from our recent meta-analysis of studies [14] con-
ducted at various times with prevalence data for the period
2001–11. Therefore, there may be confounding across dif-
ferent time periods. The DALYs are crudely measured with-
out accounting for time lag, and adjustments for any
confounders. Further refinement and the inclusion of rele-
vant associations are needed to give definitive conclusion
regarding the DALYs caused by EOD.
Furthermore, the data used in the calculation are hetero-
geneous. Prevalence data for anxiety and psychological dis-
order was obtained from the National Survey of Mental
Health and Wellbeing [67]. For depression and PTSD, the
prevalence rate from the same source is aggregated by gen-
der. This was disaggregated across age groups using census
data, based on the information that depression has similar
variation across age groups up to 64 and declining there-
after for those aged 65 and over [68]. In addition, disability
weights were obtained from a range of studies including
the GBD [69], Vos & Mathers [66], the 2005 Victorian Bur-
den of Disease Study, and Begg et al. [47]. The derivation of
these weights, particularly for psychological disorders, in-
volved averaging across studies and disease categories. For
example, the GBD [69] disaggregates the weights by age
group; Vos & Mathers [66] provide weight range while a
single weight is used in the Victorian BoD.
Our estimation does not include direct healthcare expen-
ditures and indirect costs associated with racial discrimin-
ation which can arise from inefficiency in the labour market
due to the underutilisation of education, skills and
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experiences of the targets. As such, even for the few health
outcomes for which there was the requisite data, our esti-
mates are lower bound as they only measure intangible
costs.
Therefore, the total cost is likely to be higher than 3.02%
if all cost components were included. A fuller costing of
EOD would include hospitalisation and out-of-pocket ex-
penses in addition to the BoD-based intangible cost re-
ported in Table 6. According to the AIHW, Australians
(individuals), on the average covered 17.3% of the total
health expenditure in 2000–2012 [70]. The rest of the
health cost was funded by state and federal governments
and private insurers. The AIHW [71] reports that out of
pocket expenses accounted for 18.2% of total health spend-
ing, and averaged at 2.4 to 2.8% of total household spending
in the decade ending 2009. ‘More than half of non-
government funding (58%) came from out-of-pocket pay-
ments by individuals. This included circumstances where
individuals met the full cost of goods or services, as well as
where they shared the cost, for example, with private health
insurance funds or the Australian Government through
Medicare’ (p.475). According to this report, the total out-
of-pocket spending by individuals covered $7.7 billion or
47% of the total cost of medications in the years 2009–10.
Addition of such costs attributable to EOD exposure can
therefore substantially increase the health cost of EOD.2
Finally, this study focused on Australian data. However,
the analysis can be replicated cross-nationally with poten-
tially comparable findings. The exact cost of EOD for each
country will depend on the prevalence rate of EOD, with
countries that exhibit higher EOD prevalence also bearing
higher overall cost.
Conclusion
We measured the economic impact of EOD in Australia
from the societal perspective. Economic costs are usually es-
timated based on production loss and/or the consumption of
resources. Another important cost component is the pain
and suffering involved due to illness that can be attributed to
a risk factor, such as racial discrimination. In this study, we
found the BoD attributable to EOD associated with anxiety,
depression, PTSD and psychological disorders to be substan-
tial. Overall, the four illnesses accounted for 235,452 DALYs
lost in Australia due to EOD of which depression accounted
for 31.3% of the total DALYs.
In monetary terms, for a VSL of $6.65 million, a time
period of 40 years and a discount rate of 3.3%, which is
roughly $166,250 per DALY, we estimated the cost of
EOD related to the four health outcomes to be $37.9 bil-
lion, which is roughly 3.02% of the average annual GDP
(2001–2011) of Australia [72]. This is proportional to
previous findings in U.S. studies that are based on the
human capital approach.
Using new evidence and integrating it with advances in
public health research, our study was able to estimate the
economy-wide loss directly attributable to EOD. The evi-
dence clearly shows that the Australian economy would
be significantly better off in the absence of EOD. In
addition to its infringement on the rights of individuals
and groups, racial discrimination has detrimental impact
on the economy. The cost would even be much higher if
discrimination related direct expenditures were added. As
such, the addition of hospitalisation and out-of-pocket ex-
penditure should also be estimated in future work to give
a better picture of the total health cost of EOD. The other
source of cost is the indirect costs related to loss of prod-
uctivity. As there exists little research that has estimated
this, more research is needed in this area to corroborate
the scant evidence base regarding the cost of EOD.
In summary, although we did not include a range of cost
items in our analysis, our study was able to estimate a vital
aspect of the cost of racial discrimination. We found that
racial discrimination is substantially costly to the health of
individuals expressed in loss of healthy life years. The find-
ings of this study are particularly important in informing
public policies and advocacy activities related to public
health, community social cohesion, anti-discrimination
and cultural diversity. By quantifying the cost of discrim-
ination, the study contributes to the rationale for anti-
racism strategies that seek to benefit society by reducing
the costs associated with discrimination. The findings also
indicate that given some of the costs resulting from EOD
are avoidable, measures taken by governmental and non-
governmental institutions to curb racial discrimination are
likely to be socially and economically feasible. Countries
with racially and ethnically diverse population can there-
fore realise substantial savings by enforcing effective anti-
discrimination measures [73].
Endnotes
1The inclusion criteria which can be found in Paradies
et al. [14] include:
1. be published in a journal article or dissertation
2. report at least one association between racism and a
health outcome/s
3. be an empirical study
4. report quantitative data
5. contain relevant exposure/s and/or outcome/s
6. report unadjusted associations
7. report statistics that allow calculation of effect size
For this paper, further inclusion criteria were added:
1. The study has to report at least one of four health
outcomes (depression, anxiety, PTSD and
psychological disorder).
2. It has to report statistics/data that allow for the
calculation of OR.
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2Another source of cost would be litigation cost that re-
sults if alleged racial discrimination is brought to the court.
Some of the settlement and litigation cost would be transfer
payment and may not be attributed as loss in GDP. But,
some part would be incurred as a loss to society as time
and resources are diverted to execute the litigation process.
An example for this is the $72.69 million per annum lost in
litigation cost to settle racial discrimination complaints in
the U.S. (see: a 2014 Equal Employment Opportunity
Commission report).
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Table 8 EOD attributable burden of disease (DALYs) for men in
Australia by age and causes
Type of Illness/
Health outcome
Age
category
Prevalent
cases
Disability
weight
PAF DALYs
Anxiety 17–24 92,660 0.149 0.200 2759
25–34 125,395 0.149 0.190 3542
35–44 176,308 0.149 0.162 4264
45–54 150,582 0.149 0.151 3398
55–64 79,335 0.149 0.126 1484
65–74 30,116 0.149 0.081 364
75–100 8473 0.149 0.063 80
Depression 17–24 90,907 0.283 0.200 5145
25–34 125,465 0.283 0.190 6735
35–44 131,571 0.283 0.162 6048
45–54 123,803 0.283 0.152 5310
55–64 99,971 0.283 0.126 3554
65–74 61,090 0.283 0.081 1404
75–100 38,529 0.283 0.063 692
PTSD 17–24 69,178 0.096 0.459 3045
25–34 95,475 0.096 0.442 4054
35–44 100,122 0.096 0.396 3811
45–54 94,210 0.096 0.377 3410
55–64 76,075 0.096 0.327 2391
65–74 46,488 0.096 0.23 1028
75–100 35,090 0.096 0.187 629
Psychological
disorders
17–24 296,300 0.224 0.125 8289
25–34 321,500 0.224 0.118 8490
35–44 319,000 0.224 0.100 7122
45–54 262,100 0.224 0.093 5433
55–64 126,500 0.224 0.076 2148
65–74 53,800 0.224 0.048 579
75–100 20,900 0.224 0.037 174
Total 95,379
Note: DALYs are estimated using the standard formula (3) for each illness by
age group
Table 9 EOD attributable burden of disease (DALYs) for women
in Australia by age and causes
Type of Illness/
Health outcome
Age
category
Prevalent
cases
Disability
weight
PAF DALYs
Anxiety 17–24 206,467 0.149 0.174 5359
25–34 226,359 0.149 0.166 5600
35–44 248,614 0.149 0.159 5878
45–54 235,276 0.149 0.148 5171
55–64 122,097 0.149 0.123 2241
65–74 39,403 0.149 0.086 508
75–100 21,035 0.149 0.048 150
Depression 17–24 143,311 0.283 0.174 7071
25–34 205,822 0.283 0.166 9680
35–44 220,309 0.283 0.159 9902
45–54 207,824 0.283 0.148 8683
55–64 165,160 0.283 0.123 5761
65–74 105,170 0.283 0.087 2575
75–100 82,283 0.283 0.048 1113
PTSD 17–24 122,265 0.096 0.417 4895
25–34 175,596 0.096 0.403 6794
35–44 187,956 0.096 0.39 7038
45–54 177,304 0.096 0.37 6294
55–64 140,905 0.096 0.323 4364
65–74 89,726 0.096 0.243 2092
75–100 93,117 0.096 0.145 1299
Psychological
disorders
17–24 374,800 0.224 0.108 9032
25–34 376,800 0.224 0.102 8622
35–44 397,500 0.224 0.097 8663
45–54 351,600 0.224 0.09 7087
55–64 190,200 0.224 0.074 3165
65–74 70,000 0.224 0.051 804
75–100 36,800 0.224 0.028 230
Total 140,073
Note: DALYs are estimated using the standard formula (3) for each illness by
age group
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